Table 1.
Variables of sample characterization for the nordic and free walking groups in baseline.
| Variable | NW Group (n = 16) | FW Group (n = 17) | p Value |
|---|---|---|---|
| Age (years) | 64.9 ± 10.2 | 70.5 ± 5.8 | 0.062 |
| Body mass (kg) | 79.0 ± 15.1 | 68.9 ± 11.9 | 0.041 * |
| Women, n (%) | 3 (18) | 10 (58) | 0.757 |
| Stature (m) | 1.67 ± 0.08 | 1.59 ± 0.14 | 0.049 * |
| Body Mass Index (kg/m2) | 28.5 ± 4.2 | 27.4 ± 5.8 | 0.556 |
| Fat percentage (%) | 21.42 ± 5.7 | 24.13 ± 9.3 | 0.367 |
| Length of lower limb (m) | 0.88 ± 0.02 | 0.85 ± 0.03 | 0.087 |
| Time of clinical diagnostics of PD (years) | 5.5 ± 3.3 | 5.1 ± 4.1 | 0.757 |
| UPDRS III | 15.00 ± 3.2 | 23.19 ± 3.9 | 0.128 |
| Hoehn & Yahr (scale of 1 a 4) | 1.5 ± 0.5 | 2.0 ± 1.0 | 0.123 |
| MoCA (score de 0 a 30) | 16.67 ± 1.4 | 21.96 ± 1.1 | 0.004 * |
| Berg Balance Scale | 51.19 ± 1.2 | 47.44 ± 2.5 | 0.988 |
| Clinical Symptoms | R = 7; L = 9 | R = 9; L = 7 | NA |
| Affected leg | 9 | 6 | NA |
| Instability (change of balance) | 7 | 7 | NA |
| Tremor | 6 | 8 | NA |
| Postural changes | 14 | 6 | NA |
| Rigidity | 4 | 11 | NA |
| Bradykinesia | 4 | 0 | NA |
| Dyskinesia | 3 | 2 | NA |
| Freezing | 5 | 5 | NA |
| Historic of falls | |||
| Drugs (Dosages) | 250 ± 0.0 | 181.89 ± 46.81 | NA |
| Levodopa + Carbidopa | 161 ± 53.21 | 250 ± 108.40 | NA |
| Prolopa | 150 ± 93.24 | 200 ± 0.0 | NA |
| Sifrol | - | 400 ± 0.0 | NA |
| Biperideno | - | 175 ± 75.00 | NA |
| Benserazida | - | 150. ± 00 | NA |
| Selegina |
Note: The data are in the means and standard deviations and some variables in absolute numbers. * Statistical significance at p < 0.05; NW: Nordic Walking; PD: Parkinson’s disease; UPDRS III: Unified Parkinson’s Disease Rating Scale; MoCA: Montreal Cognitive Assessment; R (right); L (Left); NA (Not Apply).